Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 89

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 89
---
 the issuance of options to purchase 504shares of common stock at a weighted average price of $436.00. As of October 1, 2024, the board of directors approved option awards to the executive officers for 2024, as set forth below:

| Name and Position                                               |     |   Stock 
 Options |
| Chris Ehrlich, Chief Executive Officer and Chairman(1)          |     |  25,500 |
| Andrew “Al” Kucharchuk, Chief Financial Officer                 |     |   5,000 |
| Kristen Pierce, Ph.D., Chief Development Officer                |     |   2,659 |
| Brian G. Atwood, Former Chief Executive Officer and Chairman(2) |     |   5,080 |
| Charles R. Carter, Former Chief Financial Officer(3)            |     |       — |
| Daniel Corey, M.D., Former Chief Technology Officer(4)          |     |       — |

____________ (1)Excludes 5,272 options granted under the 2024 Plan which were forfeited on September 30, 2024. (2)Excludes 13,318 options granted under the 2024 Plan which were forfeited on September 30, 2024. (3)Excludes 4,954 options granted under the 2024 Plan which were forfeited on September 30, 2024. (4)Excludes 4,613 options granted under the 2024 Plan which were forfeited on September 23, 2024. Equity Grant Timing Our compensation committee has generally granted equity awards on an annual basis and when it has determined necessary or appropriate for retention and recruitment, including following the successful completion of major corporate transactions or regulatory milestones. In addition, eligible employees, including our NEOs, may voluntarily enroll in our 2024 Employee Stock Purchase Plan, or ESPP, and receive an option to purchase shares at a discount using payroll deductions accumulated during the prior six months. No shares were issued under the ESPP during 2024. During 2024, our compensation committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards, and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. During 2024, we did not grant stock options to our named executive officers during any period beginning four business days before and ending one business day after the filing or furnishing of a